Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2016 | FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma

Press brief by Salah-Eddin Al-Batran, MD of the Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.